Clinical trials: Tocilizumab
Rheumatoid Arthritis
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)
This prospective, observational study will assess the effect of RoActemra/Actemra (tocilizumab) on fatigue in patients with moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01185522
- Where
- France
- Volunteers
- 719 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active…
- Trial name
- NCT00754572
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 69 sites in Argentina, Brazil and 8 more
- Volunteers
- 418 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT05091424
- Testing
- Mosunetuzumab, Tocilizumab, Venetoclax
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 332 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.
- Trial name
- NCT00144560
- Testing
- MRA(Tocilizumab)
- Volunteers
- 31 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs.
- Trial name
- NCT01617005
- Testing
- Tocilizumab
- Where
- Montenegro
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require…
- Trial name
- NCT03109470
- Sponsor
- Pope Research Corporation
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
- Trial name
- NCT07709000
- Testing
- MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine)
- Where
- 5 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy…
- Trial name
- NCT07825064
- Testing
- Cevostamab, Pomalidomide, Dexamethasone
- Where
- 2 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01277328
- Where
- Romania
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
COVID-19 Pneumonia
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe…
- Trial name
- MARIPOSA (NCT04363736)
- Testing
- Tociliuzumab
- Where
- 24 sites in United States
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
This is a phase 3 study to compare efficacy and safety of CT-P47 and RoActemra in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT05489224
- Testing
- CT-P47, EU-approved RoActemra
- Where
- Poland
- Volunteers
- 471 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants…
- Trial name
- NCT01941095
- Testing
- Azathioprine, Chloroquine, Hydroxychloroquine
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is a first-in human, open-label, Phase 1 dose-escalation study in order to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for intravenous (IV) and/or subcutaneous (SC) dosing schemes of…
- Trial name
- NCT05219513
- Testing
- RO7443904, Glofitamab, Obinutuzumab
- Where
- 9 sites in United States, Australia and 4 more
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
This is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (RA) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.
- Trial name
- NCT01187563
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Hematological Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
- Trial name
- MonumenTAL-1 (NCT04634552)
- Testing
- Talquetamab
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 510 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core…
- Trial name
- NCT01662063
- Testing
- Tocilizumab
- Where
- 79 sites in United States, Puerto Rico
- Volunteers
- 218 people
- Sponsor
- Genentech, Inc.
Systemic Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
- Trial name
- NCT00144612
- Testing
- MRA(Tocilizumab)
- Volunteers
- 60 people
- Sponsor
- Chugai Pharmaceutical
Juvenile Idiopathic Arthritis
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study.
- Trial name
- NCT01667471
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma…
- Trial name
- NCT05315713
- Testing
- Mosunetuzumab SC, Tiragolumab, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor…
- Trial name
- NCT01242488
- Testing
- CDP6038, Tocilizumab (Actemra or RoActemra)
- Where
- 82 sites in United States, Belgium and 1 more
- Volunteers
- 221 people
- Sponsor
- UCB Pharma